USA English

Brazil Português

Canada English Français

Blog
Patient Resources
Investors & Media
Careers
Contact

Our Purpose
- Supporting Access for Patients
- Our Responsibility
  - Grants and Charitable Contributions
Our Company
Our Medicines
Our Research

Blog
Patient Resources
Investors & Media
Careers
Contact

Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH)

You are about to leave the Ultragenyx website.

Do you want to continue?

Ultragenyx is not responsible for the content or availability of third party sites.

Our Purpose
- Supporting Access for Patients
- Our Responsibility
Our Company
Our Medicines
Our Research
Careers
Investors & Media

Our Other Websites

www.UltraRareAdvocacy.com
www.UltraCareSupport.com

©2021 Ultragenyx Pharmaceutical. All rights reserved.

Privacy Policy
Cookie Policy

This site uses cookies to provide you with a more responsive and personalized service. By clicking "Accept" below, you agree to the use of cookies on this site. Please read our Cookie Policy and Privacy Policy for more information on the use of cookies on this website.